Generics News

The biosimilar products are indicated for treating certain inflammatory diseases.

Posaconazole injection is supplied as single-dose vials containing 300mg of posaconazole in 16.7mL of solution.

Yuflyma is expected to be available in July 2023.

Training should be provided to patients and caregivers on how to appropriately administer Udenyca via the prefilled autoinjector.

The Cyltezo Pen 40mg/0.8mL will be available on July 1, 2023.

A biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product.

Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.

Padagis was granted 180 days of Competitive Generic Therapy exclusivity.

Dichlorphenamide tablets are supplied as 50mg tablets in 30- and 100-count bottles.

Both Hikma Pharmaceuticals and Par Pharmaceuticals will be supplying the product.